Nanodelivery of immunogenic cell death-inducers for cancer immunotherapy

Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 68, 394, 10.3322/caac.21492 Gonzalez, 2018, Roles of the immune system in cancer: from tumor initiation to metastatic progression, Genes Dev, 32, 1267, 10.1101/gad.314617.118 Galon, 2019, Approaches to treat immune hot, altered and cold tumours with combination immunotherapies, Nat Rev Drug Discov, 18, 197, 10.1038/s41573-018-0007-y Chen, 2013, Oncology meets immunology: the cancer-immunity cycle, Immunity, 39, 1, 10.1016/j.immuni.2013.07.012 Dunn, 2004, The three Es of cancer immunoediting, Annu Rev Immunol, 22, 329, 10.1146/annurev.immunol.22.012703.104803 Melero, 2014, Therapeutic vaccines for cancer: an overview of clinical trials, Nat Rev Clin Oncol, 11, 509, 10.1038/nrclinonc.2014.111 Hu, 2018, Towards personalized, tumour-specific, therapeutic vaccines for cancer, Nat Rev Immunol, 18, 168, 10.1038/nri.2017.131 Nagata, 2018, Apoptosis and clearance of apoptotic cells, Annu Rev Immunol, 36, 489, 10.1146/annurev-immunol-042617-053010 Nagata, 2017, Programmed cell death and the immune system, Nat Rev Immunol, 17, 333, 10.1038/nri.2016.153 Montico, 2018, Immunogenic apoptosis as a novel tool for anticancer vaccine development, Int J Mol Sci, 19, 594, 10.3390/ijms19020594 Gao, 2020, Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy, Acta Pharmacol Sin, 41, 986, 10.1038/s41401-020-0400-z Kroemer, 2013, Immunogenic cell death in cancer therapy, Annu Rev Immunol, 31, 51, 10.1146/annurev-immunol-032712-100008 Zhou, 2019, Immunogenic cell death in cancer therapy: present and emerging inducers, J Cell Mol Med, 23, 4854, 10.1111/jcmm.14356 Dudek, 2013, Inducers of immunogenic cancer cell death, Cytokine Growth Factor Rev, 24, 319, 10.1016/j.cytogfr.2013.01.005 Asadzadeh, 2020, Current approaches for combination therapy of cancer: the role of immunogenic cell death, Cancers (Basel), 12, 1047, 10.3390/cancers12041047 Almanza, 2019, Endoplasmic reticulum stress signalling - from basic mechanisms to clinical applications, FEBS J, 286, 241, 10.1111/febs.14608 Zeeshan, 2016, Endoplasmic reticulum stress and associated ROS, Int J Mol Sci, 17, 327, 10.3390/ijms17030327 Panaretakis, 2009, Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death, EMBO J, 28, 578, 10.1038/emboj.2009.1 Chao, 2010, Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47, Sci Transl Med, 2, 10.1126/scitranslmed.3001375 Pawaria, 2011, CD91-dependent programming of T-helper cell responses following heat shock protein immunization, Nat Commun, 2, 521, 10.1038/ncomms1524 Garg, 2013, ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death, Autophagy, 9, 1292, 10.4161/auto.25399 Liu, 2020, Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies, Theranostics, 10, 3099, 10.7150/thno.42998 Giampazolias, 2017, Mitochondrial permeabilization engages NF-kappaB-dependent anti-tumour activity under caspase deficiency, Nat Cell Biol, 19, 1116, 10.1038/ncb3596 Kroemer, 2010, Autophagy and the integrated stress response, Mol Cell, 40, 280, 10.1016/j.molcel.2010.09.023 Michaud, 2011, Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice, Science, 334, 1573, 10.1126/science.1208347 Ghiringhelli, 2009, Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors, Nat Med, 15, 1170, 10.1038/nm.2028 Garg, 2012, A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death, EMBO J, 31, 1062, 10.1038/emboj.2011.497 Livesey, 2012, p53/HMGB1 complexes regulate autophagy and apoptosis, Cancer Res, 72, 1996, 10.1158/0008-5472.CAN-11-2291 Zhu, 2015, Cytosolic HMGB1 controls the cellular autophagy/apoptosis checkpoint during inflammation, J Clin Invest, 125, 1098, 10.1172/JCI76344 Shiratsuchi, 2004, Inhibitory effect of Toll-like receptor 4 on fusion between phagosomes and endosomes/lysosomes in macrophages, J Immunol, 172, 2039, 10.4049/jimmunol.172.4.2039 Apetoh, 2007, Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy, Nat Med, 13, 1050, 10.1038/nm1622 Galluzzi, 2017, Immunogenic cell death in cancer and infectious disease, Nat Rev Immunol, 17, 97, 10.1038/nri.2016.107 Wang, 2018, Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies, Cancer Lett, 438, 17, 10.1016/j.canlet.2018.08.028 Shekarian, 2015, Paradigm shift in oncology: targeting the immune system rather than cancer cells, Mutagenesis, 30, 205, 10.1093/mutage/geu073 Casares, 2005, Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death, J Exp Med, 202, 1691, 10.1084/jem.20050915 Menger, 2012, Cardiac glycosides exert anticancer effects by inducing immunogenic cell death, Sci Transl Med, 4, 1, 10.1126/scitranslmed.3003807 Obeid, 2007, Calreticulin exposure dictates the immunogenicity of cancer cell death, Nat Med, 13, 54, 10.1038/nm1523 Tesniere, 2010, Immunogenic death of colon cancer cells treated with oxaliplatin, Oncogene, 29, 482, 10.1038/onc.2009.356 Spisek, 2007, Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications, Blood, 109, 4839, 10.1182/blood-2006-10-054221 Schiavoni, 2011, Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis, Cancer Res, 71, 768, 10.1158/0008-5472.CAN-10-2788 Chen, 2012, Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine, Cancer Immunol Immunother, 61, 1989, 10.1007/s00262-012-1258-9 Galluzzi, 2020, Consensus guidelines for the definition, detection and interpretation of immunogenic cell death, J Immunother Cancer, 8, e000337, 10.1136/jitc-2019-000337 Guo, 2020, Nano codelivery of oxaliplatin and folinic acid achieves synergistic chemo-immunotherapy with 5-fluorouracil for colorectal cancer and liver metastasis, ACS Nano, 14, 5075, 10.1021/acsnano.0c01676 Yu, 2020, Icaritin exacerbates mitophagy and synergizes with doxorubicin to induce immunogenic cell death in hepatocellular carcinoma, ACS Nano, 14, 4816, 10.1021/acsnano.0c00708 Chen, 2019, Vasodilator hydralazine promotes nanoparticle penetration in advanced desmoplastic tumors, ACS Nano, 13, 1751 Pozzi, 2016, The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death, Nat Med, 22, 624, 10.1038/nm.4078 Hossain, 2018, Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression, J Clin Invest, 128, 644, 10.1172/JCI94586 Dudek-Peric, 2015, Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin, Cancer Res, 75, 1603, 10.1158/0008-5472.CAN-14-2089 Sukkurwala, 2014, Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set, Oncoimmunology, 3, 10.4161/onci.28473 Bezu, 2018, eIF2alpha phosphorylation is pathognomonic for immunogenic cell death, Cell Death Differ, 25, 1375, 10.1038/s41418-017-0044-9 Martins, 2011, Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress, Oncogene, 30, 1147, 10.1038/onc.2010.500 Guo, 2020, Membrane-core nanoparticles for cancer nanomedicine, Adv Drug Deliv Rev, 10.1016/j.addr.2020.05.005 Choi, 2007, Renal clearance of quantum dots, Nat Biotechnol, 25, 1165, 10.1038/nbt1340 Longmire, 2008, Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats, Nanomedicine (Lond), 3, 703, 10.2217/17435889.3.5.703 Braet, 2007, Contribution of high-resolution correlative imaging techniques in the study of the liver sieve in three-dimensions, Microscopy Research and Technique, 70, 230, 10.1002/jemt.20408 Blanco, 2015, Principles of nanoparticle design for overcoming biological barriers to drug delivery, Nat Biotechnol, 33, 941, 10.1038/nbt.3330 Suk, 2016, PEGylation as a strategy for improving nanoparticle-based drug and gene delivery, Advanced Drug Delivery Reviews, 99, 28, 10.1016/j.addr.2015.09.012 Tan, 2015, Cell or cell membrane-based drug delivery systems, Theranostics, 5, 863, 10.7150/thno.11852 Piao, 2014, Erythrocyte membrane is an alternative coating to polyethylene glycol for prolonging the circulation lifetime of gold nanocages for photothermal therapy, ACS Nano, 8, 10414, 10.1021/nn503779d Kobayashi, 2013, Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?, Theranostics, 4, 81, 10.7150/thno.7193 Fang, 2011, The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect, Adv Drug Deliv Rev, 63, 136, 10.1016/j.addr.2010.04.009 Matsumura, 1986, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res, 46, 6387 Petersen, 2016, Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin, J Control Release, 232, 255, 10.1016/j.jconrel.2016.04.028 Harrington, 2001, Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes, Clin Cancer Res, 7, 243 Park, 2019, Alliance with EPR effect: combined strategies to improve the EPR effect in the tumor microenvironment, Theranostics, 9, 8073, 10.7150/thno.37198 Natfji, 2017, Parameters affecting the enhanced permeability and retention effect: the need for patient selection, J Pharm Sci, 106, 3179, 10.1016/j.xphs.2017.06.019 Norouzi, 2020, Clinical applications of nanomedicine in cancer therapy, Drug Discov Today, 25, 107, 10.1016/j.drudis.2019.09.017 Lee, 2017, (64)Cu-MM-302 positron emission tomography quantifies variability of enhanced permeability and retention of nanoparticles in relation to treatment response in patients with metastatic breast cancer, Clin Cancer Res, 23, 4190, 10.1158/1078-0432.CCR-16-3193 Ramanathan, 2017, Correlation between ferumoxytol uptake in tumor lesions by MRI and response to nanoliposomal irinotecan in patients with advanced solid tumors: a pilot study, Clin Cancer Res, 23, 3638, 10.1158/1078-0432.CCR-16-1990 Miller, 2017, Prediction of anti-cancer nanotherapy efficacy by imaging, Nanotheranostics, 1, 296, 10.7150/ntno.20564 Moghimi, 2018, Nanoparticle transport pathways into tumors, J Nanopart Res, 20, 169, 10.1007/s11051-018-4273-8 Nel, 2017, New insights into ‘permeability’ as in the enhanced permeability and retention effect of cancer nanotherapeutics, ACS Nano, 11, 9567, 10.1021/acsnano.7b07214 Sindhwani, 2020, The entry of nanoparticles into solid tumours, Nature Mater, 566, 10.1038/s41563-019-0566-2 Majumder, 2019, Nanocarrier-based systems for targeted and site specific therapeutic delivery, Adv Drug Deliv Rev, 144, 57, 10.1016/j.addr.2019.07.010 Yoo, 2019, Active targeting strategies using biological ligands for nanoparticle drug delivery systems, Cancers (Basel), 11, 640, 10.3390/cancers11050640 Bareford, 2007, Endocytic mechanisms for targeted drug delivery, Adv Drug Deliv Rev, 59, 748, 10.1016/j.addr.2007.06.008 Lino, 2018, Light-triggerable formulations for the intracellular controlled release of biomolecules, Drug Discov Today, 23, 1062, 10.1016/j.drudis.2018.01.019 Gulfam, 2019, Design strategies for chemical-stimuli-responsive programmable nanotherapeutics, Drug Discov Today, 24, 129, 10.1016/j.drudis.2018.09.019 Azevedo, 2018, Strategies for the enhanced intracellular delivery of nanomaterials, Drug Discov Today, 23, 944, 10.1016/j.drudis.2017.08.011 Dewhirst, 2017, Transport of drugs from blood vessels to tumour tissue, Nature Reviews Cancer, 17, 738, 10.1038/nrc.2017.93 Neesse, 2015, Stromal biology and therapy in pancreatic cancer: a changing paradigm, Gut, 64, 1476, 10.1136/gutjnl-2015-309304 Han, 2018, Reversal of pancreatic desmoplasia by re-educating stellate cells with a tumour microenvironment–activated nanosystem, Nat Commun, 9, 3390, 10.1038/s41467-018-05906-x Ishikawa, 2009, STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity, Nature, 461, 788, 10.1038/nature08476 Su, 2019, STING activation in cancer immunotherapy, Theranostics, 9, 7759, 10.7150/thno.37574 Shae, 2019, Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy, Nat Nanotechnol, 14, 269, 10.1038/s41565-018-0342-5 Yang, 2020, Tackling TAMs for cancer immunotherapy: it’s nano time, Trends Pharmacol Sci, 41, 701, 10.1016/j.tips.2020.08.003 Qiu, 2019, Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy, Acta Biomater, 92, 184, 10.1016/j.actbio.2019.05.030 Allen, 2013, Liposomal drug delivery systems: from concept to clinical applications, Adv Drug Deliv Rev, 65, 36, 10.1016/j.addr.2012.09.037 Mishra, 2018, Solid lipid nanoparticles: emerging colloidal nano drug delivery systems, Pharmaceutics, 10, 191, 10.3390/pharmaceutics10040191 Wang, 2015, Delivery of oligonucleotides with lipid nanoparticles, Adv Drug Deliv Rev, 87, 68, 10.1016/j.addr.2015.02.007 Wong, 2007, Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles, Adv Drug Deliv Rev, 59, 491, 10.1016/j.addr.2007.04.008 Duan, 2019, Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors, Nat Commun, 10, 1899, 10.1038/s41467-019-09221-x Li, 2018, Microfluidics for producing poly (lactic-co-glycolic acid)-based pharmaceutical nanoparticles, Adv Drug Deliv Rev, 128, 101, 10.1016/j.addr.2017.12.015 Cordeiro, 2019, Poly(beta-amino ester)-based gene delivery systems: From discovery to therapeutic applications, J Control Release, 310, 155, 10.1016/j.jconrel.2019.08.024 Bae, 2009, Intelligent polymeric micelles from functional poly(ethylene glycol)-poly(amino acid) block copolymers, Adv Drug Deliv Rev, 61, 768, 10.1016/j.addr.2009.04.016 Swierczewska, 2016, Polysaccharide-based nanoparticles for theranostic nanomedicine, Adv Drug Deliv Rev, 99, 70, 10.1016/j.addr.2015.11.015 Cabral, 2018, Block copolymer micelles in nanomedicine applications, Chem Rev, 118, 10.1021/acs.chemrev.8b00199 Chen, 2019, Nanoparticle-enhanced radiotherapy to trigger robust cancer immunotherapy, Adv Mater, 31 Kim, 2013, Inorganic nanosystems for therapeutic delivery: status and prospects, Advanced Drug Delivery Reviews, 65, 93, 10.1016/j.addr.2012.08.011 Lu, 2017, Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression, Nat Commun, 8, 1811, 10.1038/s41467-017-01651-9 Yang, 2017, Hollow MnO2 as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses, Nat Commun, 8, 902, 10.1038/s41467-017-01050-0 Prasad, 2018, Nanotherapeutics: an insight into healthcare and multi-dimensional applications in medical sector of the modern world, Biomed Pharmacother, 97, 1521, 10.1016/j.biopha.2017.11.026 Jahangirian, 2017, A review of drug delivery systems based on nanotechnology and green chemistry: green nanomedicine, Int J Nanomedicine, 12, 2957, 10.2147/IJN.S127683 Malet-Sanz, 2012, Continuous flow synthesis. A pharma perspective, J Med Chem, 55, 4062, 10.1021/jm2006029 Makgwane, 2014, Synthesis of nanomaterials by continuous-flow microfluidics: a review, J Nanosci Nanotechnol, 14, 1338, 10.1166/jnn.2014.9129 Huang, 2019, Nanoenabled reversal of IDO1-mediated immunosuppression synergizes with immunogenic chemotherapy for improved cancer therapy, Nano Lett, 19, 5356, 10.1021/acs.nanolett.9b01807 Kuai, 2018, Elimination of established tumors with nanodisc-based combination chemoimmunotherapy, Sci Adv, 4, 10.1126/sciadv.aao1736 Zhao, 2016, Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy, Biomaterials, 102, 187, 10.1016/j.biomaterials.2016.06.032 Phung, 2019, Reprogramming the T cell response to cancer by simultaneous, nanoparticle-mediated PD-L1 inhibition and immunogenic cell death, J Control Release, 315, 126, 10.1016/j.jconrel.2019.10.047 Feng, 2018, Binary cooperative prodrug nanoparticles improve immunotherapy by synergistically modulating immune tumor microenvironment, Adv Mater, 30, 10.1002/adma.201803001 Yan, 2019, Activating antitumor immunity and antimetastatic effect through polydopamine-encapsulated core–shell upconversion nanoparticles, Adv Mater, 31, 10.1002/adma.201905825 Deng, 2020, Endoplasmic reticulum targeting to amplify immunogenic cell death for cancer immunotherapy, Nano Lett, 20, 1928, 10.1021/acs.nanolett.9b05210 Li, 2019, A three-in-one immunotherapy nanoweapon via cascade-amplifying cancer-immunity cycle against tumor metastasis, relapse, and postsurgical regrowth, Nano Lett, 19, 6647, 10.1021/acs.nanolett.9b02923 Li, 2019, Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death, Nat Commun, 10, 1 Yu, 2019, Sequentially responsive biomimetic nanoparticles with optimal size in combination with checkpoint blockade for cascade synergetic treatment of breast cancer and lung metastasis, Biomaterials, 217, 10.1016/j.biomaterials.2019.119309 Chen, 2019, Tumor microenvironment-triggered aggregated magnetic nanoparticles for reinforced image-guided immunogenic chemotherapy, Adv Sci (Weinh), 6